Tesamorelin/Ipamorelin Blend

The Tesamorelin/Ipamorelin blend combines a stabilized GHRH analogue (Tesamorelin) with a selective GHSR agonist (Ipamorelin) for research into dual-pathway growth hormone axis modulation. This combination targets both GHRH receptor and ghrelin receptor signaling simultaneously.

This blend combines Tesamorelin (a stabilized GHRH analogue) with Ipamorelin (a selective GHSR agonist) for research into dual-pathway GH axis stimulation. It targets both GHRH and ghrelin receptor signaling for synergistic GH release studies. Supplied as a lyophilized peptide blend.

The rationale for combining Tesamorelin and Ipamorelin in research stems from their complementary mechanisms of action on the GH axis — Tesamorelin acting through the GHRH receptor and Ipamorelin through the GHSR/ghrelin receptor. Dual-pathway stimulation research aims to characterize synergistic effects on GH pulsatility that exceed individual compound activity.

Individual preclinical studies on each component demonstrate their respective GH secretagogue properties through distinct receptor pathways. Tesamorelin activates GHRH-R/cAMP signaling while Ipamorelin engages GHSR-dependent pathways. Combination research examines whether simultaneous dual-receptor engagement produces amplified or modified GH release kinetics compared to individual administration.